Advanced imaging, particularly PSMA PET scans, enhances detection of microscopic disease, allowing for more precise treatment ...

Nearly three years of research have brought about remarkable results for the majority of 80 patients subjected to targeted alpha therapy of metastatic prostate cancer. The first assessments - ...

Sergio Calvo, general manager of theranostics at GE HealthCare, joins MobiHealthNews to discuss how combining molecular ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) ...

This Collaboration and Exclusive Licensing Agreement expands the Company's existing portfolio of targeted alpha therapies, led by ADVC001, a first-in-class 212Pb-PSMA radioligand therapy. The ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Vascular-targeted photodynamic therapy continues to shows efficacy for partial gland ablation of intermediate-risk prostate cancer with minimal toxicity, according to long-term follow-up results from ...

Up to 85 percent of prostate cancers are diagnosed in the early stages, when they are still curable.Even when diagnosed at an advanced stage, most prostate cancers respond well to treatment. The first ...

Add Yahoo as a preferred source to see more of our stories on Google. For men facing the return of prostate cancer, a new combination therapy may offer a much longer break before the disease comes ...